Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference
- Late-breaking poster to feature new positive cardiopulmonary function results from the DELIVER trial of z-rostudirsen in DMD -
- Oral presentation on Phase 3 trial design for z-basivarsen in DM1 -
- Five total presentations across three neuromuscular diseases demonstrate strength of Dyne's pipeline based on clinically-validated FORCE™ platform -
WALTHAM, Mass., Feb. 22, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that five presentations, including three oral presentations, highlighting the company's Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and Pompe disease programs will be presented at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference being held March 8-11, 2026, in Orlando, FL, and virtually.
"Late last year, we presented positive topline results for the DELIVER trial in DMD demonstrating unprecedented breadth and durability of functional improvement across upper limb, lower limb, trunk and pulmonary muscle groups. We are excited to build on those results with the presentation of new long-term data showing potential preservation of cardiopulmonary function," said John Cox, president and chief executive officer of Dyne. "These clinical data provide further validation of our FORCE™ platform and its potential to be best-in-class in delivering a therapeutic payload across relevant tissues to drive functional improvement for patients with neuromuscular diseases. This same platform is being used across our other pipeline programs, and we are excited to also be presenting the design of a robust Phase 3 trial of z-basivarsen in DM1, which we believe will be field defining, as well as additional preclinical data for our program in Pompe disease."
Dyne's posters and presentations at the 2026 MDA Clinical & Scientific Conference will include:
- New analyses of the results of the DELIVER clinical trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in exon 51 skip amenable DMD.
- The design of a Phase 3 clinical trial assessing zeleciment basivarsen (z-basivarsen, also known as DYNE-101) in DM1.
- New preclinical data for DYNE-401, Dyne's product candidate being developed for individuals living with Pompe disease demonstrating the potential to deliver functional improvement with infrequent dosing.
Oral Presentations:
Abstract Title: Zeleciment rostudirsen significantly increased dystrophin protein levels and led to functional improvement in clinical measures in the DELIVER trial
Presentation Date and Time: Wednesday, March 11, 12:45 p.m. ET
Presenter: Kevin Flanigan M.D., Director, Center for Gene Therapy, Abigail Wexner Research Institute of Nationwide Children's Hospital in Columbus, Ohio and a Principal Investigator for the DELIVER Trial
Abstract Title: A global Phase 3 trial assessing the efficacy and safety of z-basivarsen in myotonic dystrophy type 1
Presentation Date and Time: Wednesday, March 11, 9:30 a.m. ET
Presenter: Doug Kerr M.D., Ph.D., MBA, Chief Medical Officer, Dyne Therapeutics
Abstract Title: DYNE-401 demonstrates potential to address Pompe disease with low and infrequent dosing
Presentation Date and Time: Wednesday, March 11, 11:15 a.m. ET
Presenter: Tyler Picariello Ph.D., Director, Research, Dyne Therapeutics
Each oral presentation has a corresponding poster presentation which will be available during the poster sessions on Tuesday, March 10 in the conference exhibit hall.
Poster Presentations:
Late-breaking: Zeleciment rostudirsen led to trends in long-term improvement in clinical outcomes including cardiopulmonary function: Additional data from DELIVER
Encore: Zeleciment basivarsen targets the underlying cause of DM1 to enable functional improvement in the Phase 1/2 ACHIEVE trial
-
- These results were previously presented at the 30th Annual International Congress of the World Muscle Society (WMS) in October 2025.
- These results were previously presented at the 30th Annual International Congress of the World Muscle Society (WMS) in October 2025.
The poster presentations above will be available during the poster sessions on Tuesday, March 10 and Monday, March 9, respectively, in the conference exhibit hall.
Additionally, a symposium titled "Functional improvement: Moving beyond dystrophin in DMD" will be held on March 9 at 7:00 a.m. ET.
All poster presentations will be available in the Scientific Publications & Presentations section of Dyne's website on Sunday, March 8 at 6:00 pm ET. Slides from the oral presentations and the Dyne symposium will be available on Dyne's website at the commencement of each presentation.
About Dyne Therapeutics
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as a preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Dyne's strategy, future operations, prospects and plans, objectives of management, the potential of the FORCETM platform, and the therapeutic potential of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251), zeleciment basivarsen (z-basivarsen, also known as DYNE-101) and DYNE-401, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "objective," "ongoing," "plan," "predict," "project," "potential," "should," "will," or "would," or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Dyne may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; the timing of and Dyne's ability to enroll patients in clinical trials; whether results from preclinical studies and initial data from early clinical trials will be predictive of the final results of the clinical trials or future trials or longer-term performance than is measured in the clinical trial; uncertainties as to the FDA's and other regulatory authorities' interpretation of the data from Dyne's clinical trials and acceptance of Dyne's clinical programs and the regulatory approval process, including the availability of accelerated approval pathways; whether Dyne's cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in Dyne's filings with the Securities and Exchange Commission (SEC), including the Company's most recent Form 10-Q and in subsequent filings Dyne may make with the SEC. In addition, the forward-looking statements included in this press release represent Dyne's views as of the date of this press release. Dyne anticipates that subsequent events and developments will cause its views to change. However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Dyne's views as of any date subsequent to the date of this press release.
Contacts:
Investors
Mia Tobias
[email protected]
781-317-0353
Media
Stacy Nartker
[email protected]
781-317-1938
